重组人促卵泡激素生物类似药QL1012与Gonal-f®用于卵巢刺激的比较:一项三期试验
这项在中国13个中心开展的多中心、随机、评估者盲法三期试验,纳入341例接受辅助生殖技术卵巢刺激的不孕女性,比较QL1012与Gonal-f®。取卵数均数分别为14.7±7.0与13.4±6.1,最小二乘均数差1.3个卵母细胞(95%CI -0.1至2.7;P=0.0650),在预设等效界值±3.0内。结论认为两者治疗等效且安全性相似。
要点
- QL1012组取卵数14.7±7.0,Gonal-f®组13.4±6.1,最小二乘均数差1.3(95%CI -0.1至2.7)。
- 最小二乘均数差在预设等效界值±3.0内,符合治疗等效。
- 除雌二醇浓度外,次要终点无统计学差异;卵巢过度刺激综合征发生率12.4%对13.1%。
核心结论
- 在接受辅助生殖技术卵巢刺激的女性中,QL1012与Gonal-f®显示治疗等效且安全性相似。
研究设计与样本
- 多中心、随机、评估者盲法三期试验,在中国13个中心开展。
- 纳入不孕女性,年龄20-39岁,体重指数18-30 kg/m2,月经周期规律且有辅助生殖技术指征。
- 垂体降调节成功后按1:1随机接受QL1012或Gonal-f®,按年龄分层给药(皮下注射,每日一次)。
- 符合方案集共341例,QL1012组169例,Gonal-f®组172例。
主要发现
- 取卵数均数QL1012组14.7±7.0(n=169)对Gonal-f®组13.4±6.1(n=172)。
- 经协方差分析校正后最小二乘均数差为1.3个卵母细胞(95%CI -0.1至2.7;P=0.0650),在预设等效界值±3.0内。
- 全分析集结果相似。
- 除雌二醇浓度外,次要终点无统计学差异;雌二醇中位数QL1012组3948.0 pg/ml对Gonal-f®组3545.3 pg/ml(P=0.0015)。
- 卵巢过度刺激综合征发生率QL1012组12.4%对Gonal-f®组13.1%,其他不良事件两组相似。
关键数值与推荐
- 主要终点取卵数的最小二乘均数差1.3个卵母细胞(95%CI -0.1至2.7;P=0.0650),在预设等效界值±3.0内。
- 按年龄分层的初始剂量:小于30岁75-150 IU,30-34岁150-225 IU,35岁及以上225-300 IU,皮下注射,每日一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Are QL1012 and Gonal-f® equivalent in women undergoing ovarian stimulation for assisted reproductive technology (ART)? DESIGN: This multicentre, randomized, assessor-blinded, phase-three trial was conducted at 13 centres in China. Eligible patients were infertile women; age 20-39 years; body mass index 18-30 kg/m2; regular menstrual cycles; and indication for ART. After successful pituitary downregulation, patients were randomly assigned (1:1) to receive QL1012 or Gonal-f®, stratified by age (initial dose of 75-150 IU for women younger than 30 years, 150-225 IU for women aged 30-34 years and 225-300 IU for women aged ≥35 years, subcutaneously, once daily). The primary end point was the number of oocytes retrieved. RESULTS: Between October 2018, and June 2019, 341 patients were included in the per-protocol set. The mean numbers of oocytes retrieved were 14.7 ± 7.0 in the QL1012 group (n = 169) and 13.4 ± 6.1 in the Gonal-f® group (n = 172). Adjusted by analysis of covariance model, the least-squares mean difference was 1.3 oocytes (95% CI -0.1 to 2.7; P = 0.0650), within the pre-defined equivalence margins of ±3.0. Similar results were observed in the full analysis set. Additionally, no statistical differences were found in secondary end points except oestradiol concentration (median 3948.0 pg/ml versus 3545.3 pg/ml; P = 0.0015). Ovarian hyperstimulation syndrome (12.4% versus 13.1 %) and other adverse events were similar between the two groups. CONCLUSIONS: Therapeutic equivalence and similar safety profiles were demonstrated between QL1012 and Gonal-f® in women undergoing ovarian stimulation for ART.
引用
- Hu L, Lv J, Ma Q, et al. Comparison of recombinant human FSH biosimilar QL1012 with Gonal-f® for ovarian stimulation: a phase-three trial. Reprod Biomed Online. 2022. PMID: 36621365. doi:10.1016/j.rbmo.2022.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。